Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Phase 1

Completed

Conditions: Healthy
Obesity

Interventions: Drug: Placebo
Drug: BI 1820237
Drug: BI 456906
Drug: semaglutide

First Posted Date: 2023-03-02

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 88

Registration Number: NCT05751226

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: Caffeine
Drug: Warfarin sodium
Drug: Omeprazole
Drug: Metoprolol
Drug: Midazolam

First Posted Date: 2023-02-23

Last Posted Date: 2025-01-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4

Registration Number: NCT05741385

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: Rosuvastatin
Drug: Digoxin
Drug: Metformin hydrochlorid
Drug: Furosemide

First Posted Date: 2023-02-23

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05741372

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo matching BI 1839100
Drug: BI 1839100
Drug: midazolam
Drug: digoxin
Drug: rosuvastatin

First Posted Date: 2023-02-22

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 67

Registration Number: NCT05738291

Locations: 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: BI 425809 (iclepertin)

First Posted Date: 2023-02-16

Last Posted Date: 2023-12-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05731895

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

Phase 1

Completed

Conditions: Healthy
Liver Diseases

Interventions: Drug: BI 690517

First Posted Date: 2023-02-16

Last Posted Date: 2023-05-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05731908

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Omega Research Orlando, LLC, Orlando, Florida, United States

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: BI 765250
Drug: Placebo

First Posted Date: 2023-02-15

Last Posted Date: 2025-03-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT05728489

Locations: 🇧🇬
MBAL Sveta Sofia, Sofia, Bulgaria
🇬🇪
ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia
🇲🇩
Clinical Republican Hospital "Timofei Mosneaga", Chisinau, Moldova, Republic of

and more 2 locations

A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: bosentan

First Posted Date: 2023-02-13

Last Posted Date: 2023-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT05723874

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems

Phase 1

Completed

Conditions: Renal Insufficiency
Healthy

Interventions: Drug: BI 1015550

First Posted Date: 2023-02-08

Last Posted Date: 2023-09-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT05718648

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: BI 425809

First Posted Date: 2023-02-08

Last Posted Date: 2023-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT05718843

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy